Of these cases of pDC-AML, we observed cyto-CD22 expression in 87.5% of cases, CD19 expression in 75% of cases, cyto-CD79a expression in 62.5% of cases, CD20 in 12.5% of cases, and PAX5 expression in 83.3% of cases, when applicable. This evidence concerns the gene CD79A and acute myeloid leukemia.